IFNA1 and systemic lupus erythematosus: The NEA‐1 cluster (SLE patients of non‐European ancestry with low IFN and high neutrophil/myeloid lineage/inflammation scores), although comprising the fewest number of patients, was characterized with a distinctly poorer BILAG response to rituximab, with only 12.5% of patients achieving overall response.